Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME IN PLASTIC CONTAINER versus ZINACEF IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME IN PLASTIC CONTAINER versus ZINACEF IN PLASTIC CONTAINER.
CEFEPIME IN PLASTIC CONTAINER vs ZINACEF IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3. It demonstrates broad-spectrum activity against gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking transpeptidation and leading to cell lysis and death.
1-2 g intravenously every 8-12 hours for moderate to severe infections; up to 2 g every 8 hours for severe infections or febrile neutropenia.
750 mg intravenously or intramuscularly every 8 hours; for severe infections, 1.5 g intravenously every 8 hours.
None Documented
None Documented
2.0–2.3 hours in adults with normal renal function; prolonged to 13–26 hours in end-stage renal disease.
Terminal elimination half-life is approximately 1.5 hours in adults with normal renal function; prolonged to 3-4 hours in neonates and up to 20-30 hours in end-stage renal disease.
Renal: approximately 85% of the dose excreted unchanged in urine; biliary/fecal: less than 1%.
Approximately 80-90% of the dose is excreted unchanged in the urine via glomerular filtration and tubular secretion; the remainder is eliminated via bile and feces.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic